New research reveals that fat-clogged immune cells could be a major, overlooked factor in neurodegeneration, opening up a new frontier for treatment.
For decades, the scientific narrative surrounding Alzheimer’s disease has been dominated by two notorious villains: amyloid-beta plaques and tau tangles. These sticky protein clumps have been the primary focus of countless studies and drug trials. But what if a crucial piece of the puzzle has been hiding in plain sight? New research from Purdue University suggests that the buildup of fat inside the brain’s own immune cells may be a hidden, yet powerful, driver of the disease.
This groundbreaking work, published in the journal Immunity, challenges long-held assumptions and proposes a “new lipid model of neurodegeneration.” Instead of solely targeting plaques and tangles, the scientists argue that restoring the function of the brain’s immune system by addressing this fat accumulation could be the key to fighting back against this devastating condition.
The Brain’s Overburdened Housekeepers
To understand this discovery, we first need to meet the brain’s resident immune cells: the microglia. Think of them as the brain’s dedicated housekeepers and security guards. Their job is to patrol the neural environment, clear out debris, and eliminate threats like misfolded proteins—including the amyloid-beta that forms plaques. They do this through a process called phagocytosis, essentially engulfing and breaking down unwanted material.
In a healthy brain, microglia are ruthlessly efficient. In Alzheimer’s disease, however, something goes terribly wrong. These vital cells become dysfunctional. The new study, led by Professor Gaurav Chopra, reveals a compelling reason why: they become choked with fat.
Interestingly, this isn’t a brand-new observation. Over a century ago, when Dr. Alois Alzheimer first described the disease that now bears his name, he noted not only plaques and tangles but also brain cells filled with fatty compounds called lipids. For decades, these lipid droplets were largely dismissed as insignificant by-products of the disease process. Chopra and his team, in collaboration with researchers at the Cleveland Clinic, decided to take a closer look, suspecting these fatty deposits were more than just collateral damage.
A Vicious Cycle of Fat and Dysfunction
The researchers examined brain tissue from people with Alzheimer’s and made a startling discovery. Microglia located near amyloid plaques were packed with fat. Specifically, those within a mere 10 micrometers of a plaque contained twice as many lipid droplets as microglia farther away. More importantly, these fat-laden cells were failing at their job, clearing 40% less amyloid-beta than their healthy counterparts.
This finding prompted a critical question: what was causing this fatty buildup? The investigation uncovered a destructive chain reaction. When microglia come into contact with amyloid-beta plaques and the inflammation they cause, they begin to produce an excess of free fatty acids. While these fatty acids are normally a source of energy for the cells, the disease environment throws this process into disarray.
The team identified a key culprit: an enzyme called DGAT2. This enzyme is responsible for the final step in converting free fatty acids into a stored form of fat. In the diseased microglia, DGAT2 wasn’t being produced in greater quantities, but it was failing to degrade at its normal rate. This abnormal accumulation of the enzyme acted like a switch, diverting the excess fatty acids into long-term storage. The microglia began to accumulate so much fat that they became immobilized and dysfunctional, forming what Chopra calls “lipid plaques.”
“We showed that amyloid beta is directly responsible for the fat that forms inside microglia,” Chopra explains. “Because of these fatty deposits, microglial cells become dysfunctional—they stop clearing amyloid beta and stop doing their job.” This creates a vicious cycle: plaques trigger fat accumulation, which cripples the microglia, allowing even more plaques to build up, further fueling the disease.
A New Avenue for Alzheimer’s Therapy
Pinpointing this mechanism does more than just deepen our understanding of Alzheimer’s; it reveals a completely new therapeutic target. If the accumulation of the DGAT2 enzyme is the problem, could removing it be the solution?
To find out, the research team tested two different molecules in animal models of Alzheimer’s. One molecule inhibited the function of DGAT2, while the other promoted its degradation. The results were incredibly promising. By targeting this single enzyme, they were able to reduce the fat buildup in the microglia. Freed from their fatty burden, the cells regained their ability to function properly. They started clearing amyloid-beta plaques again, and markers of neuronal health improved.
“By pinpointing this lipid burden and the DGAT2 switch that drives it, we reveal a completely new therapeutic angle: Restore microglial metabolism and you may restore the brain’s own defense against disease,” said Palak Manchanda, a first co-author of the study.
This research lays the foundation for what Chopra calls a “new lipid model of neurodegeneration.” He speculates that the specific composition of these lipid accumulations could even be a defining characteristic of different brain diseases, not just Alzheimer’s. This work shifts the focus from simply clearing out protein plaques to restoring the health and balance of the brain’s own immune system.
While this research is still in its early stages, it represents a significant and exciting shift in the fight against Alzheimer’s. By looking beyond the usual suspects and focusing on the fundamental metabolic health of the brain’s immune cells, scientists may have finally found a way to empower the brain to heal itself.
Reference
Prakash, P., Manchanda, P., Davalos, D., & Chopra, G. (2025). Brain fat, not just plaques, may be the hidden driver of Alzheimer’s. Immunity. (Note: Full publication details are based on the provided source and may be forthcoming).
